98%
921
2 minutes
20
Rationale: Clustering of social and environmental risks in low-income neighborhoods is a key factor in racial and ethnic asthma disparities. Integrating school and in-home programs, with treatment tailored to disease risk, is a promising approach for children with high disease burden.
Objectives: We evaluated the Rhode Island-Asthma Integrated Response (RI-AIR) Program in improving asthma outcomes at the individual and community levels. RI-AIR leverages existing community collaborations and technological advances to identify children with asthma at highest risk for poor outcomes through a system of identification, screening, and intervention.
Methods: We conducted a stepped wedge cluster randomized hybrid type-II effectiveness-implementation study. School-based catchment areas (n=32) of high asthma burden were identified using geospatial mapping of asthma-related urgent healthcare use from 2010-2018. Families received only school-based interventions if the child's asthma was Not Well Controlled or school and home-based interventions if the child's asthma was Poorly Controlled. Community Health Workers facilitated communication between families, schools, and healthcare providers. Follow-ups occurred every 3 months to 1-year post-intervention.
Results: Individual level: At 3-months, asthma control (primary outcome) improved (d=0.47 [95% confidence interval = 0.33; 0.61]) and symptom-free days increased (d=0.37 [0.24; 0.51]); both were sustained at 12 months. Community level: Healthcare utilization remained the same or increased (RR = 1.16 [1.00; 1.36]); however, sensitivity analyses indicated utilization was slightly lower in areas with greater family participation (penetration; active=0.93 [0.87; 0.99]; post=0.91 [0.86; 0.97]).
Conclusions: Intensive, multi-component interventions and community engagement are needed to improve asthma outcomes in areas of high burden.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1513/AnnalsATS.202501-016OC | DOI Listing |
Braz J Otorhinolaryngol
September 2025
Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo, São Paulo, SP, Brazil.
Introduction: Chronic rhinosinusitis with nasal polyp (CRSwNP) is a predominant type 2 inflammatory disease, affecting the sense of smell and quality of life. Loss of smell compromises physical and emotional health, creating negative impacts and its treatment in CRSwNP is challenging.
Aim: To present the outcomes of dupilumab in olfactory function, Nasal Polyp Score (NPS) and quality of life in Brazilian patients with severe CRSwNP.
Anal Chim Acta
November 2025
School of Materials Science and Engineering, School of Chemistry and Chemical Engineering, University of Jinan, Jinan, China. Electronic address:
Background: Bisulfite (HSO) plays crucial roles in food safety and physiological health. In the food industry, sulfur dioxide (SO) and its derivative bisulfite (HSO) are extensively employed as preservatives and bleaching agents. Nonetheless, overconsumption of bisulfite can present health hazards like asthma and potentially cancer.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
September 2025
Division of Pulmonary, Critical Care, and Sleep Medicine, National Jewish Health, Denver, Colorado, USA. Electronic address:
Background: Several real-world cohorts and numerous case reports investigating benralizumab outcomes in eosinophilic granulomatosis with polyangiitis have been published. These studies complement the limited clinical trial data available by providing early insights on benralizumab use in a broader, real-world population.
Objective: The objective of this systematic literature review (SLR) was to provide an overview of the real-world outcomes of benralizumab in EGPA.
J Allergy Clin Immunol Pract
September 2025
Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast, UK; Belfast Health and Social Care Trust, Belfast, UK.
Background: The aim of biologic therapies in severe asthma is inhibition of T2 inflammatory pathways.
Objective: We hypothesized that patients who achieve complete suppression of IL-5 & IL4/IL13 pathways with biologic therapy (FeNO <20ppb & blood eosinophil count (BEC) <0.15x10ˆ9, 'biological remission') would have better outcomes than patients with incomplete suppression of T2 biology.
Respir Med
September 2025
Department of Public Health and Infectious Diseases, Pulmonology Unit, Policlinico Umberto I, "Sapienza" University of Rome, 00185 Rome, Italy.
Purpose: Asthma and obstructive sleep apnea (OSA) are two respiratory diseases that often may coexist, resulting in Alternative Overlap Syndrome (aOVS), which is still underestimated and underdiagnosed.
Objectives: This state-of-art review aims to describe the current evidence on aOVS, including its pathophysiology, clinical, functional and therapeutic implications. A secondary objective is to assess whether aOVS can be identified as a distinct endophenotype needing personalized diagnostic and therapeutic strategies.